Vical Incorporated $VICL announced that it initiated its Phase-2 trial of HSV therapeutic DNA vaccine meant to cure genital herpes. It also said that no adverse events, grade 4 adverse events, or adverse events of special interest linked to vaccinations were observed during previous trials. The cash burn projections stays unaltered at between $8mn and $11mn for 2016, the company said.